Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease.

Liu Y, Pejchinovski M, Wang X, Fu X, Castelletti D, Watnick TJ, Arcaro A, Siwy J, Mullen W, Mischak H, Serra AL.

Sci Rep. 2018 Apr 3;8(1):5584. doi: 10.1038/s41598-018-22938-x.

2.

Kinase-targeted cancer therapies: progress, challenges and future directions.

Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, Rupasinghe HPV.

Mol Cancer. 2018 Feb 19;17(1):48. doi: 10.1186/s12943-018-0804-2. Review.

3.

Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.

Sathe A, Chalaud G, Oppolzer I, Wong KY, von Busch M, Schmid SC, Tong Z, Retz M, Gschwend JE, Schulz WA, Nawroth R.

PLoS One. 2018 Jan 22;13(1):e0190854. doi: 10.1371/journal.pone.0190854. eCollection 2018.

4.

Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer.

Park JH, Jung KH, Kim SJ, Fang Z, Yan HH, Son MK, Kim J, Kang YW, Lee JE, Han B, Lim JH, Hong SS.

Oncotarget. 2017 Dec 1;8(68):112893-112906. doi: 10.18632/oncotarget.22850. eCollection 2017 Dec 22.

5.

BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer.

Li X, Baek G, Ramanand SG, Sharp A, Gao Y, Yuan W, Welti J, Rodrigues DN, Dolling D, Figueiredo I, Sumanasuriya S, Crespo M, Aslam A, Li R, Yin Y, Mukherjee B, Kanchwala M, Hughes AM, Halsey WS, Chiang CM, Xing C, Raj GV, Burma S, de Bono J, Mani RS.

Cell Rep. 2018 Jan 16;22(3):796-808. doi: 10.1016/j.celrep.2017.12.078.

6.

Combined treatment of pancreatic cancer xenograft with 90Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor.

Aung W, Tsuji AB, Sudo H, Sugyo A, Ukai Y, Kouda K, Kurosawa Y, Furukawa T, Saga T, Higashi T.

World J Gastroenterol. 2017 Nov 14;23(42):7551-7562. doi: 10.3748/wjg.v23.i42.7551.

7.

Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.

Osoegawa A, Gills JJ, Kawabata S, Dennis PA.

Oncotarget. 2017 Jul 28;8(50):87044-87053. doi: 10.18632/oncotarget.19667. eCollection 2017 Oct 20.

8.

Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy.

Agliano A, Balarajah G, Ciobota DM, Sidhu J, Clarke PA, Jones C, Workman P, Leach MO, Al-Saffar NMS.

Oncotarget. 2017 Jul 18;8(29):47969-47983. doi: 10.18632/oncotarget.18206.

9.

DNA-damage-induced degradation of EXO1 exonuclease limits DNA end resection to ensure accurate DNA repair.

Tomimatsu N, Mukherjee B, Harris JL, Boffo FL, Hardebeck MC, Potts PR, Khanna KK, Burma S.

J Biol Chem. 2017 Jun 30;292(26):10779-10790. doi: 10.1074/jbc.M116.772475. Epub 2017 May 17.

PMID:
28515316
10.

The role of pharmacologic modulation of autophagy on anal cancer development in an HPV mouse model of carcinogenesis.

Rademacher BL, Matkowskyj KA, Meske LM, Romero A, Sleiman H, Carchman EH.

Virology. 2017 Jul;507:82-88. doi: 10.1016/j.virol.2017.04.007. Epub 2017 Apr 18.

11.

Extracellular Vesicles Mediate Radiation-Induced Systemic Bystander Signals in the Bone Marrow and Spleen.

Szatmári T, Kis D, Bogdándi EN, Benedek A, Bright S, Bowler D, Persa E, Kis E, Balogh A, Naszályi LN, Kadhim M, Sáfrány G, Lumniczky K.

Front Immunol. 2017 Mar 27;8:347. doi: 10.3389/fimmu.2017.00347. eCollection 2017.

12.

Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico drug-repurposing analysis.

Toro-Domínguez D, Carmona-Sáez P, Alarcón-Riquelme ME.

Arthritis Res Ther. 2017 Mar 11;19(1):54. doi: 10.1186/s13075-017-1263-7.

13.

Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.

Kalimutho M, Bain AL, Mukherjee B, Nag P, Nanayakkara DM, Harten SK, Harris JL, Subramanian GN, Sinha D, Shirasawa S, Srihari S, Burma S, Khanna KK.

Mol Oncol. 2017 May;11(5):470-490. doi: 10.1002/1878-0261.12040. Epub 2017 Mar 27.

14.

Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?

Thillai K, Lam H, Sarker D, Wells CM.

Oncotarget. 2017 Feb 21;8(8):14173-14191. doi: 10.18632/oncotarget.13309. Review.

15.

Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma.

Gil Del Alcazar CR, Todorova PK, Habib AA, Mukherjee B, Burma S.

Mol Cancer Res. 2016 Oct;14(10):928-940. Epub 2016 Jun 29.

16.

Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule.

Djuzenova CS, Fiedler V, Katzer A, Michel K, Deckert S, Zimmermann H, Sukhorukov VL, Flentje M.

Oncotarget. 2016 Jun 21;7(25):38191-38209. doi: 10.18632/oncotarget.9501.

17.

Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer.

Tang KJ, Constanzo JD, Venkateswaran N, Melegari M, Ilcheva M, Morales JC, Skoulidis F, Heymach JV, Boothman DA, Scaglioni PP.

Clin Cancer Res. 2016 Dec 1;22(23):5851-5863. Epub 2016 May 24.

18.

Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.

Colis LC, Herzon SB.

Bioorg Med Chem Lett. 2016 Jul 1;26(13):3122-3126. doi: 10.1016/j.bmcl.2016.04.090. Epub 2016 Apr 30.

19.

Neuroprotective effects of the anticancer drug NVP-BEZ235 (dactolisib) on amyloid-β 1-42 induced neurotoxicity and memory impairment.

Bellozi PM, Lima IV, Dória JG, Vieira ÉL, Campos AC, Candelario-Jalil E, Reis HJ, Teixeira AL, Ribeiro FM, de Oliveira AC.

Sci Rep. 2016 May 4;6:25226. doi: 10.1038/srep25226.

20.

Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair.

Udayakumar D, Pandita RK, Horikoshi N, Liu Y, Liu Q, Wong KK, Hunt CR, Gray NS, Minna JD, Pandita TK, Westover KD.

Radiat Res. 2016 May;185(5):527-38. doi: 10.1667/RR14373.1. Epub 2016 May 2.

Supplemental Content

Support Center